← All trials
NCT06279000
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2025
- Primary completion
- Mar 30, 2028
- Completion date
- Mar 30, 2029
- First posted
- Feb 26, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 880
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cantonal Hospital of St. GallenLead sponsor
- Cantonal Hospital of St. GallenSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.